NCT02030067View on ClinicalTrials.gov

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2019

Conditions
Solid TumorMetastatic Bladder Cancer
Interventions
DRUG

RX-3117

Trial Locations (12)

10021

Rexahn Site, New York

22031

Rexahn Site, Fairfax

33014

Rexahn Site, Miami Lakes

33136

Rexahn Site, Miami

35294

Rexahn Site, Birmingham

60077

Rexahn Site, Skokie

63110

Rexahn Site, St Louis

78229

Rexahn Site, San Antonio

84112

Rexahn Site, Salt Lake City

85724

Rexahn Site, Tucson

89119

Rexahn Site, Las Vegas

91010

Rexahn Site, Duarte

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT02030067 - Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | Biotech Hunter | Biotech Hunter